Fig. 1: Definition of transcriptional subtypes for PDGCs.
From: Multi-omics and pharmacological characterization of patient-derived glioma cell lines
a Schematic diagram showing the generation of PDGCs. GBM tissues from patients were dissected and digested into single-cell suspension, which was then cultured in a serum-free medium to obtain PDGCs. A total of 50 PDGCs were collected or generated in this study, of which 50 PDGCs underwent RNA-seq, 10 PDGCs underwent WES, and 49 PDGCs underwent WGS. b Oncoprint showing the genomic alterations of 50 PDGCs. HOMDEL: homozygous deletion, AMP: high-level amplification, INFRAME: in-frame insertion and deletion, MISSENSE: missense mutation, PROMOTER: mutation localized in promoters, TRUNC: truncation mutation, GAIN: low-level copy number gain, HETLOSS: heterozygous deletion. c Heatmap showing the expression levels of subtype-specific signatures. Gene expression values were normalized by z-score. The rows represent genes, and the columns represent PDGCs. d–f Barplots showing the enriched pathways by MES (d), PN (e), and OXPHOS (f) subtype. Bars were colored according to subtype identity. g, h Sankey plots showing subtype assignment (n = 45) change flow. The left columns represent subtypes defined by us and the right columns represent subtypes defined by Wang et al. 17 (g) or by Neftel et al. 18 (h). Source data are provided as a Source Data file.
